All News

TYK2i

Are TYK2 inhibitors ‘ticked’ to be part of the JAK family?

d Janet Pope, MD, MPH, FRCPC

Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.

Read Article
Back Pain

JAKi for nonradiographic axSpA

d Robert Chao, MD

One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial spondyloarthritis has been on the rise. 

Read Article
RA.Ow02.jpg

A Big Leap in Modulating Rheumatoid Disease

d Richard Conway, MBBChBAO, PhD

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid factor and antibodies to cyclic citrullinated peptides (ACPA) can precede RA disease by many years. Many, but by no means all, patients also seem to go through a pre-RA arthalgia phase of varying duration characterised by the presence of increasing joint pain without frank arthritis.

Read Article
pso.PsA_.NPF_.jpg

Updates in Psoriatic Arthritis at EULAR 2022

d Antoni Chan, MD, PhD

At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.

Read Article
Occupational and non occupational silica exposure in RA increases ILD. At home exposure was higher in women due to cleaning - talc, laundry detergents, etc. Maybe some items should be banned or people protected - ? Masks. V interesting #OP0006 @RheumNow #EULAR2022 @eular_org

Janet Pope Janetbirdope ( View Tweet)

Kading et al reports axial disease in 1/3 of patients with PsA, 55% females, 45% HLA-B27+, in 20% there was spinal but no SI joint involvement. Starts to define the Axial PsA patient as more female, less HLA-B27+ and may have only spinal inflammation #EULAR2022 @RheumNow OP0026

Dr. Antoni Chan synovialjoints ( View Tweet)

Botson et al. 152 patient RCT. MTX combo with pegloticase (to decrease antidrug abs). 6-month response (sUA<6 mg/dL) 71% vs 39%. Infusion reactions 3% vs 31%. @RheumNow #EULAR2022 OP0171 https://t.co/N29kYT3xkR https://t.co/Z4dUMD4Tt3

Links:

Richard Conway RichardPAConway ( View Tweet)
GR2 cohort prospective study of pregnancies in 126 pts w/ SpA over 15 years -Rx exposure 23% steroids, 11% NSAIDS, 55% biologics - 116 live births, 7 miscarriages, 3 stillbirths - 36.5% had unfavorable pregnancy outcomes - 19% SGA - 4.8% preterm birth #EULAR2022 @rheumnow POS1000

TheDaoIndex KDAO2011 ( View Tweet)

Important to capture MDA in the first year! Failure to achieve MDA in 1st year after PsA diagnosis associated with worse quality of life persisting despite intensified treatment. @RheumNow #EULAR2022 ABST#OP0028 https://t.co/FrO569J10S
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 OP0071 Association between long-term exposure to air pollution (fine particulate matter) and immune-mediated disease in Italy ⭐️⬆️ risk of autoimmune disease, esp RA as well as CTD, IBD ⭐️Every 10 ug/m3 increase in PM, associated with incremental 7% risk @RheumNow https://t.co/x57CXUHSHb
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 Updated ANCA Vasculitis Recommendations ⭐️Incorporates PEXIVAS and ADVOCATE findings ⭐️EGPA guidelines ⭐️PJP PPx recommendations https://t.co/CnMnxTlB1D @Rheumnow

Eric Dein ericdeinmd ( View Tweet)

No longer a "seronegative" disease? Serological collagen biomarkers (degradation markers of type I and VI collagen) can differentiate PsO pts from PsA. Potential biomarkers of MSK involvement? @RheumNow #EULAR2022 ABST#OP0031 https://t.co/vS6mD5PUxw
Robert B Chao, MD doctorRBC ( View Tweet)
6 psoriatic disease specific risk factors associated with incident cardiovascular events in PsA/PsO patients: PsO area, TJC, SJC, HAQ score, ESR, daily use of NSAIDs @RheumNow #EULAR2022 #ABSTOP0030

Robert B Chao, MD doctorRBC ( View Tweet)

NORD-STAR substudy of coagulation and fibrinolytic parameters: 〽️Impairement in eRA ⚡️Biologic parameters restored by ttmt. Effect seemed ▶️ with Biologic vs. MTX + GCs ❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn
Aurelie Najm AurelieRheumo ( View Tweet)
🚨 Depression = major comorbidity! DANBIO register 10000+ patients: ❗️10% prescription antidepressants💊 ❗️Cumulative mortality ⬆️ w/ OR>6 ❗️Particularly in age group <55 #OP0067 #EULAR2022 @RheumNow https://t.co/le8VWBFjPK
Aurelie Najm AurelieRheumo ( View Tweet)
Silverio-Antonio et al. Predictors of ILD development in MCTD. Older age at diagnosis (OR 1.1) and lymphadenopathy at presentation (OR 19.65)! predictors @RheumNow #EULAR2022 POS0901 https://t.co/IJ8Vcaga8o
Richard Conway RichardPAConway ( View Tweet)
Continue with PJP prophylaxis during the 6 months of induction Rx and until B cells repleted and if prednisone > = 20 mg/day #EULAR2022 AAV reccs @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ
Richard Conway RichardPAConway ( View Tweet)
Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷‍♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t
Janet Pope Janetbirdope ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×